PLANTATION, Fla., May 4 /PRNewswire-FirstCall/ Viragen, Inc. (Amex:
VRA; VRA.U; VRA.WS) today announced that it is scheduled to make a
presentation at the BIO International Convention to be held in Boston
during May 6-9, 2007.
Viragen's President and CEO, Mr. Charles A. Rice, will discuss
Viragen's recent Multiferon(R) European and Australian licensing
agreements, plans for the Company's anti-cancer antibodies and cytokines
and its avian transgenic biomanufacturing program (The OVA(TM) System).
Event Details:
Meeting: Biotechnology Industry Organization (BIO) International
Convention
Presenter: Charles A. Rice, President & CEO, Viragen, Inc.
Date/Time: Wednesday, May 9th at 10:00 a.m.
Place: Boston Convention & Exhibition Center, Room E
The Company will conduct additional one-on-one meetings with corporate
partnering candidates and investment bankers. To request and schedule a
meeting, please contact Douglas Calder, Director of Communications, at
(954) 233-8746 or at dcalder@viragen.com.
About Viragen, Inc.:
With international operations in the U.S., Scotland and Sweden, we are
a bio-pharmaceutical company engaged in the research, development,
manufacture and commercialization of therapeutic proteins for the treatment
of cancers and viral diseases. Our product portfolio includes:
Multiferon(R) (multi- subtype, human alpha interferon) which is uniquely
positioned in valuable niche indications, such as high-risk malignant
melanoma, and other select cancers and infectious diseases; VG102, a novel
monoclonal antibody that binds selectively to an antigen that is
significantly over-expressed on nearly all malignant tumors; and VG106, a
novel cytokine targeting difficult-to-treat cancers. We are also pioneering
the development of The OVA(TM) System with the renowned Roslin Institute,
creators of "Dolly the Sheep", as a revolutionary manufacturing platform
for the large-scale, efficient and economical production of human
therapeutic proteins and antibodies, by expressing these products in the
egg whites of transgenic hens.
For more information, please visit: http://www.Viragen.com
The foregoing press announcement contains forward-looking statements
that can be identified by such terminology such as "believes," "expects,"
"potential," "plans," "suggests," "may," "should," "could," "intends," or
similar expressions. Such forward-looking statements involve known and
unknown risks, uncertainties and other factors that may cause the actual
results to be materially different from any future results, performance or
achievements expressed or implied by such statements. In particular,
management's expectations regarding future research, development and/or
commercial results could be affected by, among other things, uncertainties
relating to clinical trials and product development; availability of future
financing; unexpected regulatory delays or government regulation generally;
the success of third- party marketing efforts; our ability to retain
third-party distributors; our ability to obtain or maintain patent and
other proprietary intellectual property protection; and competition in
general. Forward-looking statements speak only as to the date they are
made. The Company does not undertake to update forward-looking statements
to reflect circumstances or events that occur after the date the
forward-looking statements are made.
SOURCE Viragen, Inc.
 back to top
Related links:
http://www.viragen.com
http://www.bio2007.org/
CONTACT:
Douglas Calder, Director of Communications of
Viragen, Inc., +1-954-233-8746, Fax +1-954-233-1414,
dcalder@viragen.com
|
